Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art-outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
- Diez-Perez A Department of Internal Medicine, Hospital del Mar/IMIM and CIBERFES, Autonomous University of Barcelona, Passeig Maritim 25-29, 08003, Barcelona, Spain. ADiez@parcdesalutmar.cat.
- Brandi ML FirmoLab Fondazione F.I.R.M.O., Florence, Italy.
- Al-Daghri N Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.
- Branco JC NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal.
- Bruyère O WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, University of Liège, Liège, Belgium.
- Cavalli L FirmoLab Fondazione F.I.R.M.O., Florence, Italy.
- Cooper C MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK.
- Cortet B Department of Rheumatology and EA 4490, University-Hospital of Lille, Lille, France.
- Dawson-Hughes B Bone Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.
- Dimai HP Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
- Gonnelli S Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
- Hadji P Frankfurter Hormon und Osteoporose Zentrum, Frankfurt, Germany.
- Halbout P International Osteoporosis Foundation, Nyon, Switzerland.
- Kaufman JM Department of Endocrinology, Ghent University Hospital, Ghent, Belgium.
- Kurth A Department of Orthopaedic Surgery and Osteology, Klinikum Frankfurt, Frankfurt, Germany.
- Locquet M Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
- Maggi S National Research Council, Aging Program, Institute of Neuroscience, Padua, Italy.
- Matijevic R Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
- Reginster JY Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.
- Rizzoli R Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
- Thierry T Department of Rheumatology, Hospital Nord, CHU St Etienne, St Etienne, France.
- 2019-08-19
Published in:
- Aging clinical and experimental research. - 2019
Bone strength assessment
Femoral neck
Fracture risk
Lumbar spine
Osteoporosis diagnosis
REMS
Ultrasound
Absorptiometry, Photon
Bone Density
Bone and Bones
Consensus
Female
Fractures, Bone
Humans
Osteoarthritis
Osteoporosis
Risk Assessment
Spectrum Analysis
Ultrasonography
English
PURPOSE
The purpose of this paper was to review the available approaches for bone strength assessment, osteoporosis diagnosis and fracture risk prediction, and to provide insights into radiofrequency echographic multi spectrometry (REMS), a non-ionizing axial skeleton technique.
METHODS
A working group convened by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis met to review the current image-based methods for bone strength assessment and fracture risk estimation, and to discuss the clinical perspectives of REMS.
RESULTS
Areal bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) is the consolidated indicator for osteoporosis diagnosis and fracture risk assessment. A more reliable fracture risk estimation would actually require an improved assessment of bone strength, integrating also bone quality information. Several different approaches have been proposed, including additional DXA-based parameters, quantitative computed tomography, and quantitative ultrasound. Although each of them showed a somewhat improved clinical performance, none satisfied all the requirements for a widespread routine employment, which was typically hindered by unclear clinical usefulness, radiation doses, limited accessibility, or inapplicability to spine and hip, therefore leaving several clinical needs still unmet. REMS is a clinically available technology for osteoporosis diagnosis and fracture risk assessment through the estimation of BMD on the axial skeleton reference sites. Its automatic processing of unfiltered ultrasound signals provides accurate BMD values in view of fracture risk assessment.
CONCLUSIONS
New approaches for improved bone strength and fracture risk estimations are needed for a better management of osteoporotic patients. In this context, REMS represents a valuable approach for osteoporosis diagnosis and fracture risk prediction.
The purpose of this paper was to review the available approaches for bone strength assessment, osteoporosis diagnosis and fracture risk prediction, and to provide insights into radiofrequency echographic multi spectrometry (REMS), a non-ionizing axial skeleton technique.
METHODS
A working group convened by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis met to review the current image-based methods for bone strength assessment and fracture risk estimation, and to discuss the clinical perspectives of REMS.
RESULTS
Areal bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) is the consolidated indicator for osteoporosis diagnosis and fracture risk assessment. A more reliable fracture risk estimation would actually require an improved assessment of bone strength, integrating also bone quality information. Several different approaches have been proposed, including additional DXA-based parameters, quantitative computed tomography, and quantitative ultrasound. Although each of them showed a somewhat improved clinical performance, none satisfied all the requirements for a widespread routine employment, which was typically hindered by unclear clinical usefulness, radiation doses, limited accessibility, or inapplicability to spine and hip, therefore leaving several clinical needs still unmet. REMS is a clinically available technology for osteoporosis diagnosis and fracture risk assessment through the estimation of BMD on the axial skeleton reference sites. Its automatic processing of unfiltered ultrasound signals provides accurate BMD values in view of fracture risk assessment.
CONCLUSIONS
New approaches for improved bone strength and fracture risk estimations are needed for a better management of osteoporotic patients. In this context, REMS represents a valuable approach for osteoporosis diagnosis and fracture risk prediction.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1007/s40520-019-01294-4
- PMID 31422565
- Persistent URL
- https://sonar.ch/global/documents/76560
Statistics
Document views: 28
File downloads:
- fulltext.pdf: 0